Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.

Hara H, Hara H, Hironaka T, Inoue M, Iida A, Shu T, Hasegawa M, Nagai Y, Falsey AR, Kamali A, Anzala O, Sanders EJ, Karita E, Mwananyanda L, Vasan S, Lombardo A, Parks CL, Sayeed E, Krebs M, Cormier E, Ackland J, Price MA, Excler JL.

Hum Vaccin. 2011 Jun;7(6):639-45. Epub 2011 Jun 1.

PMID:
21508675
2.

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT, Allison K, Howlett N, Utech J, Allay J, Knight J, Sleep S, Meagher MM, Russell CJ, Portner A, Hurwitz JL.

Clin Vaccine Immunol. 2015 Mar;22(3):298-303. doi: 10.1128/CVI.00618-14. Epub 2014 Dec 31.

3.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team.

J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.

4.

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL.

Vaccine. 2009 Mar 13;27(12):1848-57. doi: 10.1016/j.vaccine.2009.01.041. Epub 2009 Feb 4.

5.

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.

Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, Surman S, Russell CJ, Portner A, Hurwitz JL.

Vaccine. 2008 Jun 25;26(27-28):3480-8. doi: 10.1016/j.vaccine.2008.04.022. Epub 2008 May 1.

6.

Development of an AIDS vaccine using Sendai virus vectors.

Ishii H, Matano T.

Vaccine. 2015 Nov 9;33(45):6061-5. doi: 10.1016/j.vaccine.2015.06.114. Epub 2015 Jul 29. Review.

PMID:
26232346
7.

Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques.

Moriya C, Horiba S, Inoue M, Iida A, Hara H, Shu T, Hasegawa M, Matano T.

Biochem Biophys Res Commun. 2008 Jul 11;371(4):850-4. doi: 10.1016/j.bbrc.2008.04.156. Epub 2008 May 6.

PMID:
18466766
8.

Comparison of the expression and immunogenicity of wild-type and sequence-modified HIV-1 gag genes in a recombinant Sendai virus vector.

Yu S, Feng X, Shu T, Matano T, Hasegawa M, Wang X, Li H, Li Z, Zhong R, Zeng Y.

Curr HIV Res. 2010 Apr;8(3):199-206.

PMID:
20158459
9.

Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies.

Moriya C, Horiba S, Kurihara K, Kamada T, Takahara Y, Inoue M, Iida A, Hara H, Shu T, Hasegawa M, Matano T.

Vaccine. 2011 Nov 3;29(47):8557-63. doi: 10.1016/j.vaccine.2011.09.028. Epub 2011 Sep 20.

PMID:
21939708
10.

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS, Dormitzer PR, DeVincenzo J, Hurwitz JL.

Vaccine. 2014 May 30;32(26):3264-73. doi: 10.1016/j.vaccine.2014.03.088. Epub 2014 Apr 14.

11.
12.

Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity.

Yoshizaki M, Hironaka T, Iwasaki H, Ban H, Tokusumi Y, Iida A, Nagai Y, Hasegawa M, Inoue M.

J Gene Med. 2006 Sep;8(9):1151-9.

PMID:
16841365
13.

Immunogenicity of repeated Sendai viral vector vaccination in macaques.

Kurihara K, Takahara Y, Nomura T, Ishii H, Iwamoto N, Takahashi N, Inoue M, Iida A, Hara H, Shu T, Hasegawa M, Moriya C, Matano T.

Microbes Infect. 2012 Nov;14(13):1169-76. doi: 10.1016/j.micinf.2012.07.016. Epub 2012 Jul 31.

PMID:
22884717
14.

Comparison between Sendai virus and adenovirus vectors to transduce HIV-1 genes into human dendritic cells.

Hosoya N, Miura T, Kawana-Tachikawa A, Koibuchi T, Shioda T, Odawara T, Nakamura T, Kitamura Y, Kano M, Kato A, Hasegawa M, Nagai Y, Iwamoto A.

J Med Virol. 2008 Mar;80(3):373-82. doi: 10.1002/jmv.21052.

PMID:
18205221
15.

Host specificity of the anti-interferon and anti-apoptosis activities of parainfluenza virus P/C gene products.

Chambers R, Takimoto T.

J Gen Virol. 2009 Aug;90(Pt 8):1906-15. doi: 10.1099/vir.0.011700-0. Epub 2009 May 7.

16.

First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).

Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH.

J Infect Dis. 2014 Oct 1;210(7):1052-61. doi: 10.1093/infdis/jiu217. Epub 2014 Apr 8.

17.

A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.

Liu Q, Huang W, Nie J, Zhu R, Gao D, Song A, Meng S, Xu X, Wang Y.

PLoS One. 2012;7(3):e33392. doi: 10.1371/journal.pone.0033392. Epub 2012 Mar 16.

18.

Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm.

Zhang X, Sobue T, Isshiki M, Makino S, Inoue M, Kato K, Shioda T, Ohashi T, Sato H, Komano J, Hanabusa H, Shida H.

PLoS One. 2012;7(12):e51633. doi: 10.1371/journal.pone.0051633. Epub 2012 Dec 7.

19.

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, Takimoto T, Portner A, Hurwitz JL.

Vaccine. 2012 Jan 20;30(5):959-68. doi: 10.1016/j.vaccine.2011.11.046. Epub 2011 Nov 23. Erratum in: Vaccine. 2012 Nov 6;30(48):6955. Dosage error in article text.

20.

Primary replication of a recombinant Sendai virus vector in macaques.

Kano M, Matano T, Kato A, Nakamura H, Takeda A, Suzaki Y, Ami Y, Terao K, Nagai Y.

J Gen Virol. 2002 Jun;83(Pt 6):1377-86.

PMID:
12029153

Supplemental Content

Support Center